Acute Myocardial Infarction in a Young Man with Hyperhomocysteinemia and Pulmonary Tuberculosis

Man-Yi Ren, Chun-Sheng Zhang, Xiao-Juan Zhang and Jing-Quan Zhong

Abstract

Acute myocardial infarction, hyperhomocysteinemia and pulmonary tuberculosis (PTB) are rare in individuals under the age of 30 years. We herein report the case of a 27-year-old man who presented with intermittent chest pain, elevated homocysteine level, and PTB. The patient was treated successfully with a combination of medications and percutaneous coronary intervention. This uncommon case highlights that homocysteine, folate and B vitamins levels should be regularly evaluated, and that chest X-rays or thoracic computed tomography should be ordered routinely to exclude PTB in patients under the age of 30 years who present acute myocardial infarction and lack the traditional risk factors.

Key words: acute myocardial infarction, hyperhomocysteinemia, pulmonary tuberculosis, young

(Intern Med 55: 153-159, 2016)
DOI: 10.2169/internalmedicine.55.4565)

Introduction

Acute myocardial infarction (AMI) in individuals under the age of 30 years is a rare event, which is usually not related to coronary atherosclerosis, but mostly occurs as a consequence of drug abuse, congenital coronary abnormalities, spasm, trauma, systemic vasculitis, or hematologic disease. AMI has occasionally been reported in young people with hyperhomocysteinemia (HHcy). However, there have been no real reports of AMI in young patients with pulmonary tuberculosis (PTB), much less with HHcy and PTB. Here, we present a rare case of acute anteroseptal myocardial infarction in a 27-year-old man with HHcy and PTB, who was treated successfully with a combination of medications and percutaneous coronary intervention (PCI), and analyze the etiology of the patient’s disease.

Case Report

A 27-year-old man initially presented at the end of September, 2014, to the Second Hospital of Shandong University, Jinan, China, with intermittent blunt chest pain for 9 days. He had a midnight and exertional chest pain radiating to the bilateral shoulders as well as the interscapular regions, which relieved spontaneously within 10 minutes. His cardiovascular history [including coronary artery disease (CAD), diabetes, hypertension and cerebrovascular accident (CVA)] was unremarkable (Table 1). He denied having a family history of premature CAD and hyperlipidemia. He had a history of smoking (20 cigarettes daily) for 4 years. On examination his blood pressure was 143/78 mmHg, heart rate of 74 beats/min and his body mass index was 23 kg/m². No pathological findings were detected on physical examination. An electrocardiogram (ECG) revealed rS, ST-segment elevation in leads V1 and V2 as well as T-wave inversion in lead I (Fig. 1a) while echocardiography was normal. The level of high-sensitivity troponin I was significantly elevated at 0.49 ng/mL (normal range: 0-0.06 ng/mL) whereas the levels of both myoglobin and creatine kinase-MB fraction (CKMB) were normal. The patient’s lipid profile and white blood cell count were also within the normal reference ranges. Acute anteroseptal myocardial infarction was suspected. A chest X-ray showed multiple solid nodules in the left upper lobe of lung (Fig. 2a). Thoracic computed tomography (CT) revealed PTB in the left upper lobe due to the presence of nodules of different sizes and a tree-in-bud pattern (Fig. 2b). The patient was therefore transferred to...
our hospital for further treatment two days later.

Despite the absence of fever, night sweat, weakness, cough, sputum, and hemoptysis, he was diagnosed with PTB by a pulmonologist according to the chest X-ray and CT findings, a strongly positive tuberculin skin test, and a history of close contact with a colleague who was subsequently diagnosed with PTB one year previously. The contact with the colleague amounted to a >1 month period of unconscious exposure to tuberculosis. The patient was thus administered a combination of isoniazid, rifampin, ethambutol and pyrazinamide.

HHcy was diagnosed in the course of evaluating the patient’s myocardial enzyme levels. The serum homosysteine level is one of the routinely tested for this purpose. His homosysteine level was found to be elevated at 51.4 μmol/L (normal range: 4.0-15.4 μmol/L), whereas the serum concentrations of vitamin B12 and folic acid were found to be decreased at 140.8 pg/mL (normal range: 200-900 pg/mL) and 5.3 nmol/L (normal range: 6.8-36.3 nmol/L), respectively. The patient’s serum level of vitamin B6 was 45.3 μmol/L, which is within the normal range (14.6-72.9 μmol/L). Hence, he received vitamin supplementation with vitamin B12 (25 μg, three times daily) and folic acid (5 mg, three daily).

A variety of immunological tests excluded hypothyroidism and connective tissue disease (CTD) and, importantly, systemic vasculitis (Table 1). His blood pressure on admission was 105/77 mmHg. His serum troponin I level was elevated at 0.15 μg/L (normal range: <0.01 μg/L). ECG showed rS, elevated ST segment and inverted T-waves in the leads V1-V3 as well as a flattened T-wave in lead I (Fig. 1b). The patient received a standard treatment regimen in accordance with the ST-segment elevation myocardial infarction (STEMI) protocol on the basis of smoking cessation. On the third day after admission, coronary angiography revealed 99% stenosis in the proximal segment and 80% stenosis in the mid-segment of the left anterior descending (LAD) artery with thrombolysis in myocardial infarction grade 2 (TIMI 2) flow (Fig. 3a). Furthermore, 80% stenosis was observed in the proximal segment of the second diagonal (D2) artery. The left circumflex (LCx) and right coronary arteries were normal. At the beginning of October, PCI was performed and three sirolimus-eluting stents were implanted (Fig. 3b).

During the 1-month hospitalization period, the man recovered quickly and his chest pain never recurred. His systolic blood pressure during the hospitalization period ranged from 110 to 130 mmHg and his diastolic blood pressure ranged from 60 to 80 mmHg. At discharge at the end of October, 2014, ECG was normal (Fig. 1c), and thoracic CT revealed multiple nodules of different sizes and patchy shadows of high density with cavities in the apicoposterior segment of the left upper lobe of the lung, suggesting a significant improvement over the admission (Fig. 2c). The serum concen-

Table 1. Summary of Main Laboratory Tests and History of Disease in the Patient and His Parents.

| Variable                        | Value at day | Before transfer | After admission | Father | Mother | Reference |
|--------------------------------|--------------|----------------|----------------|--------|--------|-----------|
|                                |              | 2              | 3              | 4      | 6      | 30        | 60        |
| Hs-TnI (ng/mL)                 | 0.49 (0-0.06)| -              | -              | -      | -      | -         | -         |
| CKMB (ng/mL)                   | 3.40 (0-4.0) | 1.01           | 0.76           | 0.50   | 0.42   | -         | -         |
| TnI (μg/L)                     | <0.04        | -              | -              | -      | -      | <0.01     | <0.01     |
| Hcy (μmol/L)                   | -            | 51.4           | -              | -      | -      | 30.7      | 18.9      |
| Folic acid (mmol/L)            | -            | -              | 5.3            | -      | -      | 6.0       | 24.8      |
| Vitamin B12 (μg/mL)            | -            | -              | 140.8          | -      | -      | 324.1     | 755.9     |
| Vitamin B6 (μmol/L)            | -            | 45.3           | -              | -      | -      | -         | 14.6-72.9 |
| TG (mmol/L)                    | 0.99 (0-1.8) | -              | 1.22           | -      | -      | 1.09      | 0-1.70    |
| TC (mmol/L)                    | 4.50 (3-6)   | -              | 4.28           | -      | -      | 5.53      | 0-5.20    |
| HDL (mmol/L)                   | 0.94 (0.9-1.68)| -            | 1.01           | -      | -      | 1.10      | >1.04     |
| LDL (mmol/L)                   | 2.98 (0-3.37)| -              | 2.56           | -      | -      | 2.17      | <3.12     |
| ESR (mm/h)                     | -            | -              | 8              | -      | 11     | 8         | 0-15      |
| CRP (mg/L)                     | <3.44        | -              | <3.44          | -      | -      | <3.44     | <3.44     |
| ASO (IU/mL)                    | -            | 211.0          | 184.0          | -      | -      | 162.0     | 147.0     |
| RF (IU/mL)                     | <10.1        | -              | <10.1          | -      | -      | <10.1     | <10.1     |
| CTD-related antibodies         | -            | -              | -              | -      | -      | -         | -         |
| Previous history               |              |                |                |        |        |           |           |
| Obesity                        | No           | No             | No             | No     | No     | No        | No        |
| CAD                            | No           | No             | No             | No     | No     | No        | No        |
| CVA                            | No           | No             | No             | No     | No     | No        | No        |
| DM                             | No           | No             | No             | No     | No     | No        | No        |
| CTD                            | No           | No             | No             | No     | No     | No        | No        |
| Hypertension                   | No           | No             | No             | No     | No     | No        | No        |

NOTE: Hs-TnI: high-sensitivity troponin I, CKMB: creatine kinase-MB fraction, TnI: troponin I, Hcy: homosysteine, TG: triglyceride, TC: total cholesterol, HDL: high-density lipoprotein, LDL: low-density lipoprotein, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, ASO: anti-streptolysin O, RF: rheumatoid factor, CAD: coronary artery disease, CVA: cerebrovascular accident, DM: diabetes mellitus, CTD: connective tissue disease
The young patient in our case had the classical risk factors for smoking and the two rare risk factors of HHcy and PTB. The reason why he suffered from STEMI may be attributed to two of the three risk factors, or the combination of all three.

Smoking is the single most important risk factor for CAD. Compared with nonsmokers, individuals who consume 20 or more cigarettes per day have a two- to threefold increase in the risk for total CAD (3). Additionally, in young female smokers who consume ≥20 cigarettes per day, the risk for myocardial infarction is increased 14.5-fold (4). Smoking is also the most important modifiable risk factor in young patients (5). Similarly, Larsen et al. (6) demonstrated that smoking remained a powerful contributing risk factor for new-onset STEMI in young patients. However, the high ratio of smoking as a single cardiovascular risk factor for AMI at early ages possibly comes from the spasms induced by smoking rather than from atherosclerotic stenosis (7). Actually, studies on the relationship between smoking and coronary artery lesions in patients aged <30 years with AMI were found to be lacking. In our case, the 27-year-old man smoked 20 cigarettes daily for only 4 years. Whether the single risk factor smoking was responsible for the lesions of the LAD and D2 remains unclear, however, in combination with the other uncommon factors (HHcy and PTB) it may have facilitated the development of atherosclerosis and ultimately caused the onset of STEMI.

Homocysteine is an amino acid involved in the metabolism of methionine, in which folate and vitamins B12, B6, and B2 play a key role (8). Normal total plasma homocysteine concentrations range from 5-15 μmol/L in the fasting state (9). HHcy levels are classified as moderate (15-30 μmol/L), intermediate (>30-100 μmol/L), and severe (>100 μmol/L) on the basis of concentrations measured during fasting. There is abundant epidemiologic evidence showing that the presence of mild HHcy is an independent risk factor for atherosclerosis in the coronary artery (10). Case-control and prospective studies in Norway have demonstrated that the plasma total homocysteine level is a strong, graded, and independent risk factor for CAD and stroke (11, 12). Similarly, in Japan, plasma homocysteine seems to be an independent risk factor for atherosclerotic cardiovascular disease (13). Additionally, a nested case-control study as part of the Japan Collaborative Cohort (JACC) Study confirmed that high serum homocysteine levels were associated with increased mortality from ischemic stroke, CAD and total cardiovascular disease among Japanese individuals (14). In China, the prevalence of HHcy is high, reaching 27.5%, which is similar to the incidence reported in Brazil and Lebanon, but higher than the incidence reported in Switzerland, Costa Rica, and Korea, and lower than the incidence reported in Iran, Algeria, and coastal West Africa (15). Geographically, the prevalence was high in northern areas, intermediate in central areas, and low in southern areas, and was higher inland than in coastal areas (15). Within each region,
men had higher plasma homocysteine concentrations than women. Furthermore, individuals living in urban areas had a 30% (95% CI, 1.0-1.6) greater likelihood of having high homocysteine levels than those living in rural areas (16). HHcy was not only highly prevalent but also positively associated with the presence of ischemic stroke in Chinese hypertensive patients (17, 18). Additionally, a high homocysteine level was an independent and important risk factor of CAD (19), as well as an independent predictor of 30-day cardiovascular events in patients with AMI (20), and was significantly related to cardiovascular events and all-cause death (21). In our case, the man resided in an urban area was a northerner, thereby matching two of the aforementioned features, however, he was younger than the patients in the above Chinese studies. On the other hand, it has been found that each 5 μmol/L increase in homocysteine level increases the risk of CAD by 20%, independently of traditional risk factors (22). The mean value of 51.4 μmol/L in our patient was approximately 3.5-fold above the value of the upper limits of the normal range. Therefore, although he was a smoker with PTB, this single, important risk factor may fully explain the reason why he experienced STEMI at the age of 27.

Several cases of STEMI with HHcy have been reported since 1997 (23-27). The patients (4 males and 2 females) ranged in age from 25 to 36 with homocysteine levels of 31.47-187 μmol/L. Two of the 6 patients were smokers, 1 had hypertension, 2 had hyperlipidemia, 1 had reduced folate levels, and 3 had decreased vitamin B12 concentrations. The LADs were the culprit arteries in most of the cases apart from the involvement of the LCx in one patient. The reports came to the similar conclusion that the homocysteine level predicted the coronary lesion distribution in the left main artery and the proximal or mid-LAD (28). Four of the

---

**Figure 2.** Imaging changes of pulmonary tuberculosis. (a) Chest X-ray revealing multiple solid nodules in the left upper lobe of lung. (b) Thoracic computed tomography (CT) showing pulmonary tuberculosis in the left upper lobe due to different sizes of nodules and a tree-in-bud pattern before the anti-tuberculosis therapy. (c) Thoracic CT revealing multiple nodules of different sizes and patchy shadows of high density with cavities in the apicoposterior segment of left upper lobe of lung, suggesting a significant improvement from admission following anti-tuberculosis therapy.

**Figure 3.** Coronary angiography showing 99% and 80% stenosis in the proximal and mid segments of the left anterior descending (LAD) artery with thrombolysis in myocardial infarction grade 2 (TIMI 2) flow, respectively, as well as 80% stenosis in the proximal segment of the second diagonal artery (a), and three sirolimus-eluting stents implanted in the three segments (b).
patients received medications including the dietary supplementation of folate and vitamin B₁₂, and underwent PCI (Table 2).

The nutritional deficiencies in the vitamin cofactors required for homocysteine metabolism (folate, vitamin B₁₂, and vitamin B₉) may promote HHcy. A number of other factors can increase plasma homocysteine concentrations, including: chronic renal failure, hypothyroidism, pernicious anemia, carcinoma, and some drugs and toxins. Importantly, genetic defects such as cystathionine beta-synthase deficiency and a homozygous deficiency of N₅, N⁰-methylenetetrahydrofolate reductase may lead to severe HHcy (29). Additionally, cigarette smoking can raise the plasma homocysteine level (30, 31). Smokers with high plasma homocysteine are at greatly increased risk of cardiovascular disease (30). Hence, the lack of folate and vitamin B₁₂ supplementation was effective.

Several biological mechanisms have been proposed to explain cardiovascular pathological changes associated with HHcy. These include increasing adhesion between neutrophils and endothelial cells, which impair endothelial function, accelerate the cellular uptake of modified low-density lipoprotein, thus stimulating vascular smooth muscle cell proliferation, and promoting thrombosis (32).

Therefore, it would seem necessary to normalize the homocysteine level. However, with regard to clinical trials of homocysteine reduction, several major studies on supplement with folate, vitamin B₉, and vitamin B₁₂ have shown no substantive benefits (33-35). As a group, these sharply negative trial results conflict with the supposition made from studies of mendelian randomization that had previously argued for a clear causal relationship between homocysteine concentration and vascular events (36). Despite a lack of evidence that homocysteine reduction lowers risk, there remain specific patient populations for whom homocysteine evaluation may prove appropriate, including individuals who lack traditional risk factors, patients with renal failure, or patients with markedly premature atherosclerosis (37). Therefore, folate and vitamin B₁₂ supplementation, combined with smoking cessation and moderate seafood consumption were performed to reduce the serum homocysteine level in the present patient. Actually, the re-detection of homocysteine, folate and vitamin B₁₂ levels demonstrated that the supplementation was effective.

Previous studies have demonstrated that antibodies of mycobacterial heat shock protein are associated with elevated levels of coronary calcification and early atherosclerosis, which may lead to an increased risk of cardiovascular diseases through an autoimmune process (38, 39). A recent nationwide population-based cohort study has provided compelling evidence that tuberculosis patients are at higher risk of developing acute coronary syndrome (ACS), and that the risk increases with age (40). In addition, Bakalli et al. (41) showed a rare case of AMI in a 30-year-old female patient with PTB. Kinare et al. (42) reported a severe case of a 19-year-old male who died due to a large ventricular aneurysm obtained from myocardial infarction caused by tuberculous coronaritis of the LAD branch.

### Table 2. Reported Cases of Acute Myocardial Infarction and Hyperhomocysteinemia or/and Pulmonary Tuberculosis.

| Reference | Year | Age | Gender | Diagnosis | Culprit Artery | Smoking | Serum Level | Therapy |
|-----------|------|-----|--------|-----------|---------------|---------|-------------|---------|
| Reference | 23   | 24  | 25     | 26        | 27            |         |             | Current Case |
| Year      | 1997 | 2009| 2012   | 2013      | 2014          | 2014    |             |          |
| Age       | 35   | 27  | 36     | 25        | 27            | 27      |             |          |
| Gender    | M    | M   | M      | F         | M             | M       |             |          |
| Diagnosis | STEMI| STEMI| STEMI  | STEMI      | STEMI         | STEMI   |             |          |
| Culprit Artery | LCx | LAD | LAD    | LAD       | LAD           | LAD     |             |          |
| Smoking   | No   | No  | No     | Yes       | No            | Yes     |             |          |
| Serum Level | Hey | 46.4 µmol/L | 105 µmol/L | 187 µmol/L | 31.47 µmol/L | 45.2 µmol/L | 51.4 µmol/L |
| Vitamin B₉ | NA | 12.1 mg/dL | NA | NA | NA | NA | 5.3 µmol/L |
| Therapy | NA | Medications | NA | NA | NA | NA | 45.3 µmol/L |

**NOTE:** STEMI: ST-elevation myocardial infarction, HHcy: hyperhomocysteinemia, PTB: pulmonary tuberculosis, PE: pulmonary embolism, PA: pernicious anemia, LCx: left circumflex coronary artery, LAD: left anterior descending coronary artery, NA: not available, Hey: homocysteine, PCI: percutaneous coronary intervention.
AMI. There are several reasons: 1) diffuse ST segments were elevated in all leads except AVR and V1, the PR segment was depressed in leads II and V2, and the T-waves inverted before ST-segment normalization; 2) the indications for thromblytic recanalization were not explicit; 3) the diagnosis of AMI was not verified by coronary angiography; and 4) patients with PTB seldom suffer from AMI but frequently suffer from myopericarditis. Therefore, the current case has been the first report of AMI in a young man with PTB to date. Nevertheless, the degree to which PTB was involved the patient’s development of STEMI remains unknown.

In conclusion, we presented, for the first time, a rare case of acute anteroseptal myocardial infarction in a 27-year-old man with HHcy and PTB, who was treated successfully with a combination of medications and PCI. Given that patients under 30 years of age with AMI lack the traditional risk factors, we suggest that homocysteine, folate and B vitamins levels should be regularly evaluated, and that chest X-ray or thoracic CT should be routinely ordered to exclude PTB. Aside from routine therapy and PCI, smoking cessation, the supplementation of folate, vitamin B12 and vitamin B6, as well as anti-tuberculosis treatment should be performed simultaneously when appropriate.

The authors state that they have no Conflict of Interest (COI).

Financial Support
This study was sponsored by the Natural Science Foundation of China (81270238), the Scientific Research Foundation for the Doctoral Degree, State Education Ministry of China (20100131110059) and was supported by the Scientific Development Plan of Shandong Province of China (2012G0021850).

References
1. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103: 2705-2710, 2001.
2. Gupta A, Wang Y, Spertus JA, et al. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol 64: 337-345, 2014.
3. Ridker PM, Libby P, Buring JE. Risk markers for atherothrombotic disease. In: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Bonow RO, Mann DL, Zipes DP. Libby PEB, Eds. Elsevier Saunders, Philadelphia, 2012: 914.
4. Dunn NR, Faragher B, Thorogood M, et al. Risk of myocardial infarction in young female smokers. Heart 82: 581-583, 1999.
5. Barbash GI, White HD, Modan M, et al. Acute myocardial infarction in the young—the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Eur Heart J 16: 313-316, 1995.
6. Larsen GK, Seth M, Gurn HS. The ongoing importance of smoking as a powerful risk factor for ST-segment elevation myocardial infarction in young patients. JAMA Intern Med 173: 1261-1262, 2013.
7. Yetkin E, Tekin GO, Yagmur J, Turhan H. Effects of smoking on myocardial infarction at early ages. Int J Cardiol 120: 134-135, 2007.
8. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med 246: 425-454, 1999.
9. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 39: 1764-1779, 1993.
10. Stamper MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-881, 1992.
11. Amesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 24: 704-709, 1995.
12. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337: 230-236, 1997.
13. Kario K. Is homocysteine an independent cardiovascular risk factor also in Japanese?. Intern Med 40: 1168-1169, 2001.
14. Cui R, Moriyama Y, Koike KA, et al. Serum total homocysteine concentrations and risk of mortality from stroke and coronary heart disease in Japanese: The JACC study. Atherosclerosis 198: 412-418, 2008.
15. Yang B, Fan S, Zhi X, et al. Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis. Nutrients 7: 74-90, 2014.
16. Hao L, Ma J, Zhu J, et al. High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B12, and vitamin B-6 status. J Nutr 137: 407-413, 2007.
17. Wang Y, Li X, Qin X, et al. Prevalence of hyperhomocysteinemia and its major determinants in rural Chinese hypertensive patients aged 45-75 years. Br J Nutr 109: 1284-1293, 2013.
18. Wang CY, Chen ZW, Zhang T, et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med 25: 538-544, 2014.
19. Ni M, Zhang XH, Jiang SL, Zhang Y. Homocysteineemia as an independent risk factor in the Chinese population at a high risk of coronary artery disease. Am J Cardiol 100: 455-458, 2007.
20. Ma Y, Li L, Geng XB, et al. Correlation between hyperhomocysteinemia and outcomes of patients with acute myocardial infarction. Am J Ther (Epub ahead of print).
21. Sun Y, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT. Use of serum homocysteine to predict stroke, coronary heart disease and death in ethnic Chinese. 12-year prospective cohort study. Circ J 73: 1423-1430, 2009.
22. Lentz SR, Haynes WG. Homocysteine: is it a clinically important cardiovascular risk factor? Cleve Clin J Med 71: 729-734, 2004.
23. Glueck CJ, Fontaine RN, Gupta A, Alasmi M. Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C. Metabolism 46: 1470-1472, 1997.
24. Melhem A, Desai A, Hofmann MA. Acute myocardial infarction and pulmonary embolism in a young man with pernicious anemia-induced severe hyperhomocysteinemia. Thromb J 7: 5, 2009.
25. Ukahukuwu V, Idris S, McIiwee A. Acute myocardial infarction in a young patient with hyperhomocysteinemia. BMJ Case Rep 2012: 2012.
26. Gokay S, Cicek D, Muderisoglu H. Hyperhomocysteinemia in a young woman presenting with acute myocardial infarction: Case report. Interv Med Appl Sci 5: 39-42, 2013.
27. Peoples K, Kobe D, Campagna C, Simon E. Hyperhomocysteinemia-induced myocardial infarction in a young man using anabolic steroids. Am J Emerg Med 32: 948.e1-948.e2, 2014.
28. Koz C, Celebi H, Yokusoglu M, et al. The relation between coronary lesion distribution and risk factors in young adults. Anadolu Kardiyol Derg 9: 91-95, 2009.
29. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338: 1042-1050, 1998.
30. O’Callaghan P, Meleady R, Fitzgerald T, Graham I, European Cg.
Smoking and plasma homocysteine. Eur Heart J 23: 1580-1586, 2002.
31. Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Najjar MF. Effect of cigarette smoking on plasma homocysteine concentrations. Clin Chem Lab Med 49: 479-483, 2011.
32. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 8: 100-106, 2006.
33. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673-2681, 2004.
34. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578-1588, 2006.
35. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577, 2006.
36. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 365: 224-232, 2005.
37. Loscalzo J. Homocysteine trials—clear outcomes for complex reasons. N Engl J Med 354: 1629-1632, 2006.
38. Zhu J, Katz RJ, Quyyumi AA, et al. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels: suggestion of pathogen-triggered autoimmunity in early atherosclerosis. Circulation 109: 36-41, 2004.
39. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 19: 387-394, 1998.
40. Chung WS, Lin CL, Hung CT, et al. Tuberculosis increases the subsequent risk of acute coronary syndrome: a nationwide population-based cohort study. Int J Tuberc Lung Dis 18: 79-83, 2014.
41. Bakalli A, Osmani B, Kamberi L, Pllana E. Acute myocardial infarction and pulmonary tuberculosis in a young female patient: a case report. Cases J 1: 246, 2008.
42. Kinare SG, Bhatia BI. Tuberculous coronary arteritis with aneurysm of the ventricular septum. Tuberc Leuk 30: 613-616, 1971.
43. Rodríguez Y, de Armas Y, Capo V, Wissmann G, Goldani LZ, De Waard JH. Sudden death related to tuberculous coronary arteritis. Int J Cardiol 156: e28-e29, 2012.